J. Belghiti, G. Kayem, V. Tsatsaris, F. Goffinet, B. M. Sibai et al., Benefits and risks of expectant management of severe preeclampsia at less than 26 weeks gestation: the impact of gestational age and severe fetal growth restriction, Am J Obstet Gynecol, vol.205, issue.5, pp.1-6, 2011.

B. Mol, C. T. Roberts, S. Thangaratinam, L. A. Magee, C. De-groot et al., Pre-eclampsia, Lancet Lond Engl, vol.2, 2015.

S. E. Maynard, J. Min, J. Merchan, K. Lim, J. Li et al., Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, J Clin Invest, vol.111, issue.5, pp.649-58, 2003.

R. J. Levine, S. E. Maynard, C. Qian, K. Lim, L. J. England et al., Circulating angiogenic factors and the risk of preeclampsia, N Engl J Med, vol.350, issue.7, pp.672-83, 2004.

S. Venkatesha, M. Toporsian, C. Lam, J. Hanai, T. Mammoto et al., Soluble endoglin contributes to the pathogenesis of preeclampsia, Nat Med, vol.12, issue.6, pp.642-651, 2006.

R. J. Levine, C. Lam, C. Qian, K. F. Yu, S. E. Maynard et al., Soluble endoglin and other circulating antiangiogenic factors in preeclampsia, N Engl J Med, vol.355, issue.10, pp.992-1005, 2006.

A. Luttun and P. Carmeliet, Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered?, J Clin Invest, vol.111, issue.5, pp.600-602, 2003.

V. Eremina, M. Sood, J. Haigh, A. Nagy, G. Lajoie et al., Glomerularspecific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases, J Clin Invest, vol.111, issue.5, pp.707-723, 2003.

V. Eremina, J. A. Jefferson, J. Kowalewska, H. Hochster, M. Haas et al., VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, vol.358, issue.11, pp.1129-1165, 2008.

R. Thadhani, T. Kisner, H. Hagmann, V. Bossung, S. Noack et al., Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia, Circulation, vol.124, issue.8, pp.940-50, 2011.

R. Thadhani, H. Hagmann, W. Schaarschmidt, B. Roth, T. Cingoez et al., Removal of soluble fms-like tyrosine Kinase-1 by dextran sulfate apheresis in Preeclampsia, J Am Soc Nephrol JASN, p.24, 2015.

F. Lavainne, E. Meffray, R. J. Pepper, M. Néel, C. Delcroix et al., Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc-Eur Ren Assoc, vol.29, issue.6, pp.1225-1256, 2014.

S. B. Nadler, J. H. Hidalgo, and T. Bloch, Prediction of blood volume in normal human adults, Surgery, vol.51, issue.2, pp.224-256, 1962.

S. Kojima, M. Ogi, Y. Yoshitomi, M. Kuramochi, J. Ikeda et al., Changes in bradykinin and prostaglandins plasma levels during dextransulfate low-density-lipoprotein apheresis, Int J Artif Organs, vol.20, issue.3, pp.178-83, 1997.

K. Winkler, C. Contini, B. König, B. Krumrey, G. Pütz et al., Treatment of very preterm preeclampsia via heparin-mediated extracorporeal LDL-precipitation, Pregnancy Hypertens, vol.12, pp.136-179, 2018.